Tweets
#1462 🔬Rx persistence in PsA; Guselkumab (GUS) v. IL17Ai
💡 GUS (n=910) persistence @ 12 months (67%) almost 2X IL-17Ai (n=2743) (50%)
⏳ Median time to discontinuation: GUS not reached v 12.3 months for IL-17Ai.
🔴Durable therapy ❓better outcomes
#ACR @RheumNow https://t.co/LfA3WygNVq
Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )
1 year 2 months ago
Reset the bar for remission (off steroids)!! Session #17S19
3% higher risk of organ damage for each 1mg of pred
Remission possible in rheum with lower dose GC regimen and faster taper #GCStewardship
#ACR24 @RheumNow @BethIWallace
Jiha Lee @JihaRheum ( View Tweet )
1 year 2 months ago
Single centre experience of belimumab at @GSTTnhs
@RheumNow #ACR24 https://t.co/c4jlEPRwen
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 2 months ago
In case you needed more encouragement for recombinant zoster vaccination in RA patients:
it prevents herpes zoster episodes, in the real world.
RA pts in KP system
n=1926 vaccinated matched 1:3 with non-vaccinated
- HZ reduced 60%
- PHN reduced 88%
#ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5
David Liew @drdavidliew ( View Tweet )
1 year 2 months ago
Petri on Steroids in SLE
Steroid-related organ damage presents later
- organ damage is higher in African-Americans
Dose response for prednisone and CVD risk
Each 1 mg prednisone = 3% increase risk in organ damage!
#ACR24 @jhrheumatology
@RheumNow https://t.co/00S1mxrXJp
Links:
Eric Dein @ericdeinmd ( View Tweet )
1 year 2 months ago
Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data
https://t.co/86J4HWKeIv
@RheumNow #ACR24 https://t.co/QYqj5rKHIH
Links:
Eric Dein @ericdeinmd ( View Tweet )
1 year 2 months ago
A systematic review reveals significant sex-related differences in efficacy and safety outcomes in axial spondyloarthritis (axSpA) trials. Males show higher response rates to advanced therapies compared to females. Out of 79 RCTs, only a fraction reported sex-disaggregated data.… https://t.co/dkMRK4ZYHF
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 2 months ago
Give a listen to my @RheumNow interview w Josh Hsieh, a rising star at #ACR24, who is presenting his first (of many) research project as a high school sophomore!
His work w @NamrataRheum explores what is known- & not yet known- for cancer survival in RA
https://t.co/boqwpP9CUK https://t.co/UQ37pyvZT6
Eric Dein @ericdeinmd ( View Tweet )
1 year 2 months ago
Quaack etlal. PreCARA study (vs PARA, historical control). T2T in RA improves fertility - time to pregnancy 84 days vs 196 days. T2T strategy also led to less NSAIDs and prednisolone. @RheumNow #ACR24 Abstr#1647 #ACRbest https://t.co/vYCCUqpCLo https://t.co/PUHJOxgGbL
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
#2282
🔬 Personalised Approach to TNFi in RA
📊 N=50👇; 43 responders
🔑 Findings
💥TNFR2 rs1061622 polymorphism linked to TNFi response
💥 MR/RR alleles ⬆️ 10X odds non-response v. MM allele (OR = 10.1,p=0.04)
🎯Genotyping may guide personalized RA therapy.
#ACR24 @RheumNow https://t.co/MQKZUCEPxj
Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )
1 year 2 months ago
#1330
🔬F-Calprotectin in Early RA
➡️ New-onset RA pts(n=104) had ⬆️ F-calprotectin vs controls(n=50)(71 v. 17µg/g; p<0.001)
🔑Higher F-calprotectin linked to ⬆️ DAS28 & NSAID use
⬇️levels @ 6 months Rx
❓Role of subclinical gut inflammation in early RA
#ACR24 @RheumNow
Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )
1 year 2 months ago
GILZ is a negative regulator of the GC receptor, a potential steroid sparer target.
Dr. Miceli et al identified an E3 ligase of GILZ "E3-X" where deficiency leads to ⬆️ GILZ & ⬇️ inflammation.
More studies needed but a promising steroid sparer option.
@Rheumnow #ACR24 abs1646 https://t.co/GuVMkgOTXT
Links:
sheila @RHEUMarampa ( View Tweet )
1 year 2 months ago
